Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00143975 |
Recruitment Status :
Completed
First Posted : September 2, 2005
Last Update Posted : August 12, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
GO-A-HAM:
Gemtuzumab Ozogamicin 3g/m² day 1 Cytarabine 3g/m² bid days 1-3 Mitoxantrone 12mg/m² days 2,3 All-trans Retinoic acid 45mg/m² days 4-6 and 15 mg/m² days 7-28
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Leukemia, Myeloid, Acute | Drug: Cytarabine Drug: Mitoxantrone Drug: Gemtuzumab Ozogamicin Drug: All-trans-Retinoid Acid | Phase 2 |
Primary refractory AML is associated with an extremely poor prognosis [1,2]. In the AMLHD93 trial conducted by the AMLSG ULM, patients refractory to the first induction therapy with ICE (idarubicin, cytarabine, etoposide) had an overall survival of 12% after 5 years [1]. All patients alive in this cohort had received allogeneic transplantation. Therefore, we assigned allogeneic transplantation in our consecutive trial, AMLHD98A, to all primary refractory patients [3]. However, the main problem in this patient group remains achieving a partial (PR) or complete (CR) remission to a salvage therapy. Additionally, the pre-transplant disease status is an important prognostic factor in most studies of allogeneic transplantation, regardless dose intensified or dose reduced conditioning regimens are used [4,5,6]. Since 1993, in all studies of the German-Austrian-AMLSG response-adapted treatment strategies had been used. Within the AMLHD93 trial, refractory patients were assigned to an intensified second induction regimen with S-HAM (age<55 years) [7] or HAM (age 55 to 60 years) [1], and in the AMLHD98A trial, with A-HAM [3]. The incorporation of all-trans-retinoic acid was based on in vitro data [8-13] and by our randomised AMLHD98B study for elderly AML-patients showing a benefit in primary response and survival for patients assigned to standard induction therapy in combination with ATRA [14].
To compare the different salvage therapy strategies, we performed an as-treated analysis in primary refractory patients of the different cohorts. Although refractory to the first induction therapy with ICE, nine patients received a second cycle ICE. The results summarized in table 1 showed an improved response rate (CR and PR) for patients treated with the A-HAM protocol and thus leading to a higher proportion of patients receiving an allogeneic transplantation. Survival analysis showed so far no difference between the 4 different groups. Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 conjugated to Calicheamicin. The efficacy and the toxicity profile has been evaluated in several studies, so far the substance is approved for the monotherapy in relapsed AML-patients in a dose of 9mg/m² q 14d [15]. However, used as a single agent the efficacy is limited and not durable. Therefore, several trials have evaluated GO in combination with conventional chemotherapy [16,17]. In the MRC study a dose of 6 mg/m² given once at day 1 was associated with an increased liver toxicity and therefore the study continues with a dose of 3 mg/m² once at day 1 of induction therapy [17]. In summary, the available data for combination therapy showed efficacy of GO in phase II trials. The dose limiting toxicity was defined in the MRC trial at 6 mg/m². Therefore we consider GO in combination with A-HAM for primary refractory adult AML patients. Because all primary refractory patients are candidates for an allogeneic transplantation special considerations have to be taken with respect to the development of VOD after allogeneic transplantation. One recent report suggests a substantial risk for VOD for patients receiving an allogeneic transplantation after a therapy with GO [18]. In this report the odds ratio for VOD after a therapy with GO within 3.5 months before allogeneic transplantation was 21.6 (95%-confidence interval 4.2-112.2%). However, this report is based on 62 patients and the dosage of GO used was 6mg/m² and 9mg/m². Therefore, holding in mind the risk of VOD after GO exposure and the extremely poor prognosis of primary refractory patients the treatment approach combining A-HAM with GO with a dose of 3mg/m² is justified.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 95 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase II Study on Gemtuzumab Ozogamicin in Combination With All-trans-Retinoic Acid, High-dose Cytarabine and Mitoxantrone in Patients With Primary Refractory Acute Myeloid Leukemia |
Study Start Date : | June 2004 |
Actual Primary Completion Date : | July 2007 |
Actual Study Completion Date : | June 2009 |

- Drug: Cytarabine
3 g/m2 bid. i.v day 1-3
- Drug: Mitoxantrone
12 mg/m2 i.v. day 2 and 3
- Drug: Gemtuzumab Ozogamicin
3mg/m² i.v. day 1
- Drug: All-trans-Retinoid Acid
45 mg/m2 p.o. day 4-6 15 mg/m2 p.o. day 7-28
- CR-rate after therapy with GO-A-HAM [ Time Frame: day 30 ]
- kind, incidence, severity, temporal sequence and correlation of side effects of the study-drugs [ Time Frame: 30 days ]
- rate of veno occlusive disease (VOD) after allogene transplantation [ Time Frame: 100 days after allogene transplantation ]
- overall survival [ Time Frame: two years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Acute myeloid leukemia defined according the WHO classification not responding to first induction therapy
- Age 18-60 years
- Written informed consent
Exclusion Criteria:
- Acute promyelocytic leukemia
- Uncontrolled infection
- Transfusion-refractory thrombocytopenia
- Pregnancy, breast-feeding, insufficient contraception
- Organ insufficiency: kidneys, liver, lungs, heart
- Severe neurological and psychiatrical interfering with informed consent
- No consent for the registration, storage and processing of data concerning the characteristics of the AML and the individual course
- Performance status > grad 2 according the WHO classification

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00143975
Austria | |
Department of Hematology / Oncology, University Hospital of Innsbruck | |
Innsbruck, Austria, A-6020 | |
St. Johann Hospital, Clinical Center of Salzburg | |
Salzburg, Austria, A-5020 | |
Medical Department III, Hanusch-Hospital | |
Wien, Austria, A-1140 | |
Germany | |
Medical Department II, Central Hospital of Augsburg | |
Augsburg, Germany, 86156 | |
Department of General Internal Medicine, University Hospital of Bonn | |
Bonn, Germany, 53127 | |
Department of Hematology and Oncology, Hospital Essen-Süd, Ev. Hospital of Essen-Werden | |
Essen, Germany, 45239 | |
Department of Internal Medicine III, City Hospital Frankfurt am Main - Höchst | |
Frankfurt, Germany, 65929 | |
Medical Department IV, University Hospital of Gießen | |
Gießen, Germany, 35392 | |
Department of Internal Medicine, Wilhelm-Anton-Hospital gGmbH | |
Goch, Germany, 47574 | |
Centre of Internal Medicine, University Hospital of Göttingen | |
Göttingen, Germany, 37075 | |
Department of Oncology and Hematology, University Hospital Eppendorf | |
Hamburg, Germany, 20246 | |
Medical Department III, Clinical Center Hanau | |
Hanau, Germany, 63450 | |
Medical Department III, Clinical Center Hannover-Siloah | |
Hannover, Germany, 30449 | |
Department of Hematology, Hemostaseology and Oncology, Medizinische Hochschule Hannover | |
Hannover, Germany, 30625 | |
Department of Internal Medicine I, University Hospital of Saarland | |
Homburg, Germany, 66421 | |
Medical Department II, City Hospital Karlsruhe gGmbH | |
Karlsruhe, Germany, 76133 | |
Medical Department II, University Hospital of Kiel | |
Kiel, Germany, 24116 | |
Department of Internal Medicine / Hematology and Oncology, Caritas Hospital Lebach | |
Lebach, Germany, 66822 | |
Department of Hematology / Oncology, Clinical center of Lüdenscheid | |
Luedenscheid, Germany, 58515 | |
Department of Hematology and internal Oncology, University Hospital of Mainz | |
Mainz, Germany, 55101 | |
Medical Department III, Clinical Center rechts der Isar | |
München, Germany, 81675 | |
Department of Hematology and Oncology, Clinical Center of Oldenburg gGmbH | |
Oldenburg, Germany, 26133 | |
Department of Hematology and Oncology / Caritas Hospital St. Theresia | |
Saarbrucken, Germany, 66113 | |
Department of Oncology / Clinical Center of Stuttgart | |
Stuttgart, Germany, 70174 | |
Department of Internal Medicine II, University Hospital of Tübingen | |
Tübingen, Germany, 72076 | |
Department of Internal Medicine III, University of Ulm | |
Ulm, Germany, 89070 | |
Medical Department I, Helios Hospital Wuppertal | |
Wuppertal, Germany, 42283 |
Principal Investigator: | Richard F Schlenk, Dr. med. | University of Ulm / Department of Internal Medicine III |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Prof. Dr. Reinhard Marre, University of Ulm |
ClinicalTrials.gov Identifier: | NCT00143975 History of Changes |
Other Study ID Numbers: |
AMLSG05-04 |
First Posted: | September 2, 2005 Key Record Dates |
Last Update Posted: | August 12, 2010 |
Last Verified: | August 2010 |
Acute myeloid leukemia gemtuzumab ozogamicin refractory disease |
Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Neoplasms by Histologic Type Neoplasms Cytarabine Mitoxantrone Gemtuzumab Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |
Antiviral Agents Anti-Infective Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Analgesics Sensory System Agents Peripheral Nervous System Agents Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Antineoplastic Agents, Immunological |